<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The variable rate of missed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in endoscopic biopsies and lack of other biomarkers reduce the effectiveness of surveillance programs in <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Based on the "field cancerization" hypothesis that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> arise within a transformed field with an altered biochemical phenotype, we sought to test if metabolic profiling could differentiate between histologically <z:mpath ids='MPATH_458'>normal</z:mpath> tissue from individuals with and without <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-five patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and 52 age-matched controls participated in the study </plain></SENT>
<SENT sid="3" pm="."><plain>Using 1H magic angle <z:mp ids='MP_0001411'>spinning</z:mp>-nuclear magnetic resonance spectroscopy of intact tissue, we generated metabolic profiles of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue, proximal histologically <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients (PHINOM), and proximal histologically <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa from a control group </plain></SENT>
<SENT sid="4" pm="."><plain>Using multivariate regression and receiver-operator characteristic analysis, we identified a panel of metabolites discriminating malignant and histologically <z:mpath ids='MPATH_458'>normal</z:mpath> tissues from <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients and from that of controls </plain></SENT>
<SENT sid="5" pm="."><plain>Whereas 26% and 12% of the spectral profile regions were uniquely discriminating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> or control tissue, respectively, 5% of the profile exhibited a significant progressive change in signal intensity from controls to PHINOM to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Regions identified were assigned to <z:chebi fb="0" ids="36700">phosphocholine</z:chebi> (PC), <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> (Glu), <z:chebi fb="0" ids="17268">myo-inositol</z:chebi>, <z:chebi fb="3" ids="16335">adenosine</z:chebi>-containing compounds, <z:chebi fb="0" ids="16704">uridine</z:chebi>-containing compounds, and <z:chebi fb="0" ids="17596">inosine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In particular, the PC/Glu ratio in histologically <z:mpath ids='MPATH_458'>normal</z:mpath> tissue signified the presence of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> (n=123; area under the curve, 0.84; P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, our findings support the hypothesis of the presence of metabonomic field effects in <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e>, even in non-Barrett's segments </plain></SENT>
<SENT sid="9" pm="."><plain>This indicates that metabolic profiling of tissue can potentially play a role in the surveillance of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> by reporting on the phenotypic consequences of field cancerization </plain></SENT>
</text></document>